Linscomb & Williams Inc. Has $249,000 Stake in Clorox Company (The) (CLX)

Linscomb & Williams Inc. maintained its position in shares of Clorox Company (The) (NYSE:CLX) during the fourth quarter, Holdings Channel reports. The firm owned 2,076 shares of the company’s stock at the end of the fourth quarter. Linscomb & Williams Inc.’s holdings in Clorox Company (The) were worth $249,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Salem Investment Counselors Inc. purchased a new stake in Clorox Company (The) during the third quarter valued at about $100,000. Mascoma Wealth Management LLC purchased a new stake in Clorox Company (The) during the fourth quarter valued at about $104,000. Valley National Advisers Inc. increased its stake in Clorox Company (The) by 0.5% in the third quarter. Valley National Advisers Inc. now owns 849 shares of the company’s stock valued at $106,000 after buying an additional 4 shares during the period. Bartlett & Co. LLC increased its stake in Clorox Company (The) by 13.8% in the third quarter. Bartlett & Co. LLC now owns 865 shares of the company’s stock valued at $108,000 after buying an additional 105 shares during the period. Finally, Van Hulzen Asset Management LLC purchased a new stake in Clorox Company (The) during the third quarter valued at about $113,000. 70.39% of the stock is currently owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Clorox Company (The) (NYSE:CLX)

Clorox Company (NYSE:CLX) traded down 0.29% on Friday, hitting $127.03. 1,110,272 shares of the stock traded hands. The firm has a market cap of $16.29 billion, a price-to-earnings ratio of 25.48 and a beta of 0.32. The stock has a 50-day moving average of $121.75 and a 200-day moving average of $122.58. Clorox Company has a 12-month low of $111.24 and a 12-month high of $140.47.

Clorox Company (The) (NYSE:CLX) last issued its quarterly earnings data on Friday, February 3rd. The company reported $1.25 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.22 by $0.03. Clorox Company (The) had a net margin of 11.15% and a return on equity of 239.42%. The business earned $1.41 billion during the quarter, compared to analysts’ expectations of $1.41 billion. During the same period in the previous year, the company earned $1.14 earnings per share. Clorox Company (The)’s revenue for the quarter was up 4.5% on a year-over-year basis. Analysts forecast that Clorox Company will post $5.34 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 5th. Stockholders of record on Wednesday, April 19th will be paid a $0.80 dividend. This represents a $3.20 dividend on an annualized basis and a dividend yield of 2.52%. The ex-dividend date of this dividend is Monday, April 17th. Clorox Company (The)’s payout ratio is 64.13%.

TRADEMARK VIOLATION WARNING: This story was posted by sleekmoney and is the property of of sleekmoney. If you are accessing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark legislation. The original version of this story can be viewed at http://sleekmoney.com/linscomb-williams-inc-has-249000-stake-in-clorox-company-the-clx/1656733.html.

Several research firms recently issued reports on CLX. B. Riley reaffirmed a “neutral” rating and set a $125.00 price target on shares of Clorox Company (The) in a research note on Monday, February 6th. Zacks Investment Research raised shares of Clorox Company (The) from a “strong sell” rating to a “hold” rating in a research note on Tuesday, January 3rd. Barclays PLC raised shares of Clorox Company (The) from an “underweight” rating to an “equal weight” rating and dropped their price target for the stock from $115.00 to $111.00 in a research note on Monday, January 9th. Finally, Morgan Stanley raised shares of Clorox Company (The) from an “underweight” rating to an “equal weight” rating and set a $112.00 price target on the stock in a research note on Friday, December 16th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and two have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $126.92.

In other news, Director A D. David Mackay acquired 5,000 shares of Clorox Company (The) stock in a transaction dated Thursday, December 1st. The stock was acquired at an average cost of $114.90 per share, for a total transaction of $574,500.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.74% of the stock is currently owned by insiders.

Clorox Company (The) Company Profile

The Clorox Company is a manufacturer and marketer of consumer and professional products. The Company sells its products primarily through mass retail outlets, e-commerce channels, wholesale distributors and medical supply distributors. The Company operates through four segments: Cleaning, Household, Lifestyle and International.

5 Day Chart for NYSE:CLX

Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clorox Company (The) (NYSE:CLX).

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/linscomb-williams-inc-has-249000-stake-in-clorox-company-the-clx/1656733.html

Receive News & Ratings for Clorox Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox Company (The) and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *